Previous 10 | Next 10 |
JERUSALEM , Sept. 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented a...
JERUSALEM , Sept. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in September. HC Wainwright 21 st Annual Global Investment Confere...
Nano cap Intec Pharma ( NTEC +42.3% ) is up on more than a 12x surge in volume. Investors are apparently excited that CEO Jeffrey Meckler and board member John Kozarich purchased a total of 200K shares according to insider buying data provider The Washington Service . More news on: Inte...
Intec Pharma (NASDAQ: NTEC ): Q2 GAAP EPS of -$0.30 in-line. More news on: Intec Pharma Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
JERUSALEM , Aug. 9, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and six months ended June 30 , 2019. Highlights of the second quarter 2019 and recent weeks include: Comple...
Introduction On Monday, Intec Pharma ( NTEC ) announced their phase 3 trial assessing their proprietary Accordion Pill-Carbidopa/Levodopa for Parkinson's disease did not prove superior to immediate-release Carbidopa/Levodopa (Sinemet). We are disappointed that the ACCORDANCE stud...
Intec Pharma (NASDAQ: NTEC ) -82% after Accordion Pill flunks late-stage Parkinson's study More news on: Intec Pharma Ltd., Neuralstem, Inc., Midatech Pharma Plc, Stocks on the move, Read more ...
JERUSALEM , July 22, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces top-line data from the Company's pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion Pill ® -Carbidopa/Levodopa (AP...
Gainers: Immuron (NASDAQ: IMRN ) +81% . Blue Apron Holdings (NYSE: APRN ) +49% . Moxian (NASDAQ: MOXC ) +35% . GAIN Capital Holdings (NYSE: GCAP ) +32% . Lonestar Resources (NASDAQ: LONE ) +19% . AVROBIO (NASDAQ: AVRO ) +17% . Dolphin Entertainment (NASDAQ: DLPN ) +16% . Bio-P...
Horizons ETFs Rebalances Marijuana-Focused ETFs Canada NewsWire TORONTO, July 3, 2019 TORONTO , July 3, 2019 /CNW/ - Horizons ETFs Management ( Canada ) Inc. (" Horizons ETFs ") has completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana L...
News, Short Squeeze, Breakout and More Instantly...
Intec Pharma Ltd. Company Name:
NTEC Stock Symbol:
NASDAQ Market:
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This gr...
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for t...
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, was proud to unveil its poster at the 2024 Annual Meeting of the American Association for Cance...